Aclaris Therapeutics, Inc.
ACRS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $191,696 | $73,299 | $1,027,120 | $824,863 |
| - Cash | $24,570 | $39,878 | $45,277 | $27,349 |
| + Debt | $2,598 | $3,500 | $2,254 | $2,894 |
| Enterprise Value | $169,724 | $36,921 | $984,097 | $800,408 |
| Revenue | $18,720 | $31,249 | $29,752 | $6,761 |
| % Growth | -40.1% | 5% | 340.1% | – |
| Gross Profit | $15,928 | $13,168 | $17,792 | $2,048 |
| % Margin | 85.1% | 42.1% | 59.8% | 30.3% |
| EBITDA | -$51,720 | -$115,451 | -$84,357 | -$64,461 |
| % Margin | -276.3% | -369.5% | -283.5% | -953.4% |
| Net Income | -$132,065 | -$88,481 | -$86,908 | -$90,865 |
| % Margin | -705.5% | -283.1% | -292.1% | -1,344% |
| EPS Diluted | -1.71 | -1.27 | -1.33 | -1.6 |
| % Growth | -34.6% | 4.5% | 16.9% | – |
| Operating Cash Flow | -$20,075 | -$78,325 | -$67,567 | -$52,134 |
| Capital Expenditures | -$121 | -$1,309 | -$605 | -$308 |
| Free Cash Flow | -$20,196 | -$79,634 | -$68,172 | -$52,442 |